Smith & Nephew plc (NYSE:SNN)

Smith & Nephew plc SNN

Healthcare - Medical - Devices - NYSE - GB

Watchlist

$ 30.26

3.52 %

$ 13.2 B

Market Cap

32.23

P/E

1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one SNN stock under the worst case scenario is HIDDEN Compared to the current market price of 30.3 USD, Smith & Nephew plc is HIDDEN

SNN Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one SNN stock under the base case scenario is HIDDEN Compared to the current market price of 30.3 USD, Smith & Nephew plc is HIDDEN

SNN Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one SNN stock under the best case scenario is HIDDEN Compared to the current market price of 30.3 USD, Smith & Nephew plc is HIDDEN

SNN Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart SNN

FINANCIALS

Annual
Quarterly

657 M OPERATING INCOME

987 M OPERATING CASH FLOW

-569 M INVESTING CASH FLOW

-86 M FINANCING CASH FLOW

329 M OPERATING INCOME

749 M OPERATING CASH FLOW

-209 M INVESTING CASH FLOW

-458 M FINANCING CASH FLOW

Balance Sheet Smith & Nephew plc

10.4 B ASSETS
5.09 B LIABILITIES

Current Assets	4.42 B
Cash & Short-Term Investments	619 M
Receivables	1.21 B
Other Current Assets	2.6 B
Non-Current Assets	5.93 B
Long-Term Investments	16 M
PP&E	1.42 B
Other Non-Current Assets	4.5 B

Current Liabilities	1.53 B
Accounts Payable	1.08 B
Short-Term Debt	63 M
Other Current Liabilities	386 M
Non-Current Liabilities	3.56 B
Long-Term Debt	3.26 B
Other Non-Current Liabilities	300 M

EFFICIENCY

Earnings Waterfall Smith & Nephew plc

Revenue	5.81 B
Cost Of Revenue	1.76 B
Gross Profit	4.05 B
Operating Expenses	3.39 B
Operating Income	657 M
Other Expenses	245 M
Net Income	412 M

RATIOS

11.31% OPERATING MARGIN

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Smith & Nephew plc

Net Income	412 M
Depreciation & Amortization	580 M
Capital Expenditures	-381 M
Stock-Based Compensation	40 M
Change in Working Capital	-123 M
Others	78 M
Free Cash Flow	606 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Smith & Nephew plc

Wall Street analysts predict an average 1-year price target for SNN of $27 , with forecasts ranging from a low of $27 to a high of $27 .

SNN Lowest Price Target Wall Street Target

27 USD -10.77%

SNN Average Price Target Wall Street Target

27 USD -10.77%

SNN Highest Price Target Wall Street Target

27 USD -10.77%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0.462 USD DIVIDEND PER SHARE

5. COMPETITION

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally.

-127 USD

KIDS

Overvalued 701.51%

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments.

48.1 USD

ITGR

Overvalued 60.37%

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies.

6.18 USD

BRKR

Overvalued 83.79%

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.

76.2 USD

CNMD

Undervalued 34.26%

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

6. Ownership

Insider Ownership Smith & Nephew plc

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
No data available in table

7. News

Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA). globenewswire.com - 2 weeks ago

Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹* The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week globenewswire.com - 1 month ago

Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland “CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a months-long roadshow across central Europe to promote its CORI Surgical System – an advanced robotics-assisted surgical platform for total knee and hip joint replacement procedures. The tour will commence in Berlin today and make dozens of stops at surgical facilities across Germany, Austria and Switzerland until returning to Berlin on 28 October for DKOU 2025 – the largest Orthopaedics congress in Europe. globenewswire.com - 1 month ago

Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript Smith & Nephew plc (NYSE:SNN ) Q1 2025 Results Conference Call April 30, 2025 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Julien Dormois - Jefferies Jack Reynolds-Clark - RBC Capital Markets Lisa Clive - Bernstein Hassan Al-Wakeel - Barclays Kane Slutzkin - Deutsche Bank David Adlington - JPMorgan Veronika Dubajova - Citi Dylan van Haaften - Stifel Robert Davies - Morgan Stanley Operator Ladies and gentlemen, welcome to the Smith & Nephew Q1 Trading Report. My name is Jenny, and I will be coordinating your call today. seekingalpha.com - 1 month ago

Smith & Nephew shares jump 7% on better-than-expected quarterly growth Smith & Nephew PLC (LSE:SN) rose as much as 7% in afternoon trading on Wednesday after the medical technology group reported stronger-than-expected revenue growth in the first quarter of 2025. The London-listed company posted underlying revenue growth of 3.1% in the three months to March, ahead market consensus of 1.9%. proactiveinvestors.co.uk - 1 month ago

Smith & Nephew jumps as hip and knee replacements in demand Smith & Nephew PLC (LSE:SN) shares rose over 5% to top the early FTSE 100 leaderboard on Wednesday after the knee and hip replacer maintained its full-year 2025 guidance after seeing growth of 3.1% in underlying revenue for the first quarter. The performance was supported by recent product launches and continued operational improvements across its business lines, with total reported revenue up 1.6% to $1.4 billion after a negative foreign exchange, ongoing headwinds from China and one fewer trading day compared to the prior year. proactiveinvestors.co.uk - 1 month ago

Is Smith & Nephew SNATS (SNN) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago

New Strong Buy Stocks for April 29th MATX, SNN, ALEX, PCB and LTH have been added to the Zacks Rank #1 (Strong Buy) List on April 29, 2025. zacks.com - 1 month ago

Smith & Nephew: Underappreciated Recovery With Strategic Upside Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers, the company shows visible margin improvement, offering a compelling value proposition for investors. The base case projects 35% upside by 2025 with a 20% trading margin, while the bull case suggests 50-60% upside with further margin gains. seekingalpha.com - 1 month ago

Trump tariffs: these two European healthcare stocks face the highest US revenue exposure Global financial markets are in turmoil this morning after the US President announced sweeping tariffs on several countries in a push to lower the nation's trade deficit. Trump's new tariffs are particularly expected to hurt European companies with significant revenue exposure to the United States. invezz.com - 2 months ago

Smith & Nephew falls after downgrade by leading investment bank Shares in Smith & Nephew PLC (LSE:SN) fell 2% after UBS downgraded stock in the med-tech firm to 'neutral' from 'buy' on valuation grounds. The price target remains at £12.50. proactiveinvestors.co.uk - 3 months ago

Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: globenewswire.com - 3 months ago

8. Profile Summary

Smith & Nephew plc SNN

COUNTRY GB

INDUSTRY Medical - Devices

MARKET CAP $ 13.2 B

Dividend Yield 0.00%

Description Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Contact Building 5, Watford, WD18 8YE https://www.smith-nephew.com

IPO Date Nov. 16, 1999

Employees 17349

Officers Mr. Philip G. Cowdy Chief Corporate Development & Corporate Affairs Officer Mr. Charles Reynolds Head of Corporate Communication Dr. Deepak S. Nath Ph.D. Chief Executive Officer & Director Ms. Helen Barraclough Group General Counsel & Company Secretary Dr. Vasant Padmanabhan Ph.D. President of Research & Development and Ear, Nose & Throat Mr. Paul Connolly President of Global Operations Ms. Alison Parkes Chief Compliance Officer & Compliance APAC Ms. Elga Lohler Chief Human Resources Officer Mr. Andrew Swift Head of Investor Relations Mr. John Terence Rogers Chief Financial Officer & Executive Director

Price Chart SNN

Smith & Nephew plc SNN

Free

Unlimited Plan

Premium Plan